There actually is a need to wait because both safety and efficacy data collection require blinding. If you break the seal on blinding to report out efficacy data then the seal is broken for safety, too. That would compromise the quality of the trial.
Since the company updated the clinical trial record after the last patient accrued to the trial and kept the completion date at 30JUN when it did so, I think we just have to assume either the safety checks are in fact going beyond 30JUN or that the data has been slow in being released or both.
Market Data 
Markets 
AI
